[Different clinical patterns of secondary drug failure in diabetes mellitus type II patients and their significance for diagnosis of secondary sulfonamide resistance]. / Prakticheskoe znachenie klinicheskoi kharakteristiki bol'nykh sakharnym diabetom II tipa s neéffektivnoi terapiei dlia diagnostiki vtorichnoi sul'fanilamidnoi rezistentnosti.

Peroral sugar-reducing agents have come to be routinely used in type II diabetes mellitus. The chief representatives of this group of preparations are derivatives of sulfonylurea. However, following a certain period of time effective utilization of sulfonylamides, there develops of secondary drug failure in type II diabetic patients. It is shown that patients with secondary failure represent from the clinical pathophysiological and genetic standpoints a heterogenous group.

[Current approaches to treatment of secondary sulfonylamide drug resistance in Type II diabetes mellitus]. / Sovremennye podkhody k lecheniiu vtorichnoi sul'fanilamidnoi rezistentnosti pri sakharnom diabete II tipa.

A differentiated approach toward treating secondary sulfanilamide resistance in patients with type II diabetes and proposed therapeutic regimens simple enough to be adopted in the management of the patients in question permit achieving satisfactory hypoglycemic effect maintaining an acceptable level of glucose in the blood.

[Insulin monotherapy in patients with diabetes mellitus type 2 developing secondary resistance to sulfanilamide preparations]. / Monoterapiia insulinom bol'nykh sakharnym diabetom II tipa pri razvitii vtorichnoi rezistentnosti k sul'fanilamidnym preparatam.

Patients with type-II diabetes mellitus differ widely in degrees of beta-cell functional activity, with some of them requiring insulinization as a corrective measure for hyperglycemia. It is a well-chosen and a propitious treatment option in those patients presenting with secondary resistance to sulfa drugs.

[The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance]. / Primenenie ingibitora al'fa-gliukozidazy akarbozy dlia lecheniia sakharnogo diabeta II tipa pri vtorichnoi sul'fanilamidorezistentnosti.

Efficacy was studied of acarbose in patients with type II diabetes mellitus during the development of secondary sulfamide resistance. 63 patients were evaluated. Studies were made involving glycemia on an empty stomach, postprandial glycemia and 24-h glucosuria in order that we might learn about the above drug's efficacy. High confidence level decrease in postprandial glycemia was recorded as was significant reduction in diurnal glucosuria.

[The clinical characteristics of patients with type-2 diabetes mellitus]. / Klinicheskaia kharakteristika bol'nykh sakharnym diabetom II tipa.

Results are submitted of analysis of correlation between clinical efficacy of sulphanilamide drug preparations and endogenous reserves of insulin. As many as 102 patients with type II diabetes mellitus under varying efficacy of sulphanilamides, 15 patients with type I disease and 10 essentially healthy subjects were examined. Lack of effect from peroral therapy in case of secondary sulphanilamide resistance was found to be related to the insulin endogenous reserves diminution, which feature manifests itself by reduction of the body mass and therefore adipose tissue as well, in the human organism. The insulin-producing apparatus of beta-cells tends to get low in the glucose tolerance test, which fact is evidenced by lack of the blood glucose level control.

[An analysis of the causes of low-efficacy treatment in type-2 diabetes mellitus using sulfonylurea derivatives]. / Analiz prichin nedostatochnoi éffektivnosti lecheniia sakharnogo diabeta II tipa proizvodnymi sul'fonilmocheviny.

Peroral sugar-reducing agents have come to be routinely used in the treatment of type-II diabetes mellitus. The chief representatives of this group of drug preparations are derivatives of sulfonylurea. However, following a certain period of time of effective utilization of sulfanilamides, there develops secondary sulfanilamide resistance. An analysis has been performed of causes of low effectiveness of sulfonylurea derivatives in the treatment of type-II diabetes mellitus. Errors in the policy of treating diabetes mellitus with the above drug preparations are analysed as are causes of secondary insulin dependence.

[The prevalence of secondary resistance to peroral hypoglycemic agents among patients with type-2 diabetes mellitus]. / Rasprostranennost' vtorichnoi rezistentnosti k peroral'nym sakharosnizhaiushchim sredstvam sredi bol'nykh sakharnym diabetom II tipa.

Prevalence of secondary resistance to peroral sugar-reducing agents (PSRA) among patients with type II diabetes mellitus was studied. The majority of patients (81%) who were allocated to insulin treatment for the first time had received peroral sugar-reducing preparation prior to that treatment. Mean duration of illness in these patients was 9.94 +/- 0.6 years. Females predominated among those persons showing resistance to PSRA; they all presented with obesity.